Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pegcetacoplan

pegcetacoplan

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of pegcetacoplan

10 trials tracked of pegcetacoplan: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 47 citations.

10Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 4 Phase 1 3
  1. Phase 3 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Completed · 47 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed · 18 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Completed
  4. Phase 2 A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation Completed
  5. Phase 2 A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Completed
  6. Phase 2 Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Completed
Show 4 more trials
  1. Phase 2 Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Completed
  2. Phase 1 Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. Completed
  3. Phase 1 A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Completed
  4. Phase 1 Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Complement-targeted therapies show clinical activity in C3G and aHUS including 68% reduction in proteinuria
Drug Pipeline Meta-analysis
Complement-targeted therapies show clinical activity in C3G and aHUS including 68% reduction in proteinuria Newer therapies show promise for rare kidney and blood conditions
This narrative synthesis of 38 studies evaluates complement-targeted therapies for patients with C3G and aHUS. The review highlights positiv…
Newer treatments like iptacopan and pegcetacoplan may help manage serious kidney issues and blood disorders in specific patient groups.
Frontiers Aug 24, 2026